INS and diabetes mellitus: Given that the diabetes treatments work to promote insulin secretion (sulphonylureas, dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide‐1 receptor agonists) or to promote insulin action (thiazolidinediones) or independently of the insulin secretion/sensitivity axis (sodium‐glucose cotransporter‐2 inhibitors, metformin), it would seem logical that these drugs would work well in particular patient subgroups.